Dapiprazole
Not to be confused with Aripiprazole.
|  | |
| Systematic (IUPAC) name | |
|---|---|
| 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8- tetrahydro-[1,2,4]triazolo[4,5-a]pyridine | |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information | 
| MedlinePlus | a601043 | 
| Pregnancy category | 
 | 
| Routes of administration | Topical (eye drops) | 
| Legal status | 
 | 
| Pharmacokinetic data | |
| Bioavailability | Negligible when administered topically | 
| Identifiers | |
| CAS Number | 72822-12-9  | 
| ATC code | S01EX02 (WHO) | 
| PubChem | CID 3033538 | 
| IUPHAR/BPS | 7155 | 
| DrugBank | DB00298  | 
| ChemSpider | 2298190  | 
| UNII | 5RNZ8GJO7K  | 
| KEGG | D07775  | 
| ChEBI | CHEBI:51066  | 
| ChEMBL | CHEMBL1201216  | 
| Chemical data | |
| Formula | C19H27N5 | 
| Molar mass | 325.451 g/mol | 
| 
 | |
| 
 | |
|   (what is this?)  (verify) | |
Dapiprazole (Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination.[1]
References
- ↑ Doughty, Michael J.; Lyle, William M. (May 1992). "A Review of the Clinical Pharmacokinetics of Pilocarpine, Moxisylyte (Thymoxamine), and Dapiprazole in the Reversal of Diagnostic Pupillary Dilation". Optometry & Vision Science 69 (5).
| 
 | ||||||||||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.